FDA 483 - GlaxoSmithKline Biologicals Kft. - January 31, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
GlaxoSmithKline Biologicals Kft. in Godollo, Hungary, a licensed biological drug manufacturer, was cited for two observations during an FDA inspection. The firm failed to adequately investigate manufacturing discrepancies, including particulate contamination and temperature excursions, by not assessing worst-case conditions. Additionally, procedures for accepting and rejecting manufacturing components were found to be inadequate, lacking proper risk assessments for materials containing foreign matter.
ID · b7349afb-33ba-469d-92f5-19f16080b357